156 related articles for article (PubMed ID: 7553687)
1. Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.
Kudoh S; Wang Q; Hidalgo OF; Rayman P; Tubbs RR; Edinger MG; Kolenko V; Panuto J; Bukowski R; Finke JH
Cancer Immunol Immunother; 1995 Sep; 41(3):175-84. PubMed ID: 7553687
[TBL] [Abstract][Full Text] [Related]
2. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.
Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J
J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12.
Ulchaker J; Panuto J; Rayman P; Novick A; Elson P; Tubbs R; Finke JH; Bukowski RM
J Immunother; 1999 Jan; 22(1):71-9. PubMed ID: 9924702
[TBL] [Abstract][Full Text] [Related]
4. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
5. CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.
Agrawal S; Marquet J; Delfau-Larue MH; Copie-Bergman C; Jouault H; Reyes F; Bensussan A; Farcet JP
J Clin Invest; 1998 Nov; 102(9):1715-23. PubMed ID: 9802885
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes.
Filgueira L; Zuber M; Juretic A; Lüscher U; Caetano V; Harder F; Garotta G; Heberer M; Spagnoli GC
Cell Immunol; 1993 Aug; 150(1):205-18. PubMed ID: 8343966
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
Salmeron MA; Morita T; Seki H; Platsoucas CD; Itoh K
Cancer Immunol Immunother; 1992; 35(3):211-7. PubMed ID: 1386286
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: neuroblastoma.
Facchetti P; Prigione I; Ghiotto F; Tasso P; Garaventa A; Pistoia V
Cancer Immunol Immunother; 1996 Mar; 42(3):170-8. PubMed ID: 8640845
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
Finke JH; Rayman P; Hart L; Alexander JP; Edinger MG; Tubbs RR; Klein E; Tuason L; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1994 Feb; 15(2):91-104. PubMed ID: 7907918
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.
Burdach S; Zessack N; Dilloo D; Shatsky M; Thompson D; Levitt L
J Clin Invest; 1991 Jun; 87(6):2114-21. PubMed ID: 1828253
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin's lymphomas.
Chaperot L; Delfau-Larue MH; Jacob MC; Molens JP; Roussel B; Agrawal S; Farcet JP; Gressin R; Sotto JJ; Bensa JC; Plumas J
Exp Hematol; 1999 Jul; 27(7):1185-93. PubMed ID: 10390194
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma.
Sica D; Rayman P; Stanley J; Edinger M; Tubbs RR; Klein E; Bukowski R; Finke JH
Int J Cancer; 1993 Apr; 53(6):941-7. PubMed ID: 8473051
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Smith CV; Pecorelli S; Radominska-Pandya A; Cannon MJ; Parham GP
Gynecol Obstet Invest; 2001; 51(4):254-61. PubMed ID: 11408737
[TBL] [Abstract][Full Text] [Related]
14. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction between anti-CD3 and IL-2 demonstrated by proliferative response, interferon production, and non-MHC-restricted killing.
Tovar Z; Dauphinée M; Talal N
Cell Immunol; 1988 Nov; 117(1):12-21. PubMed ID: 2972393
[TBL] [Abstract][Full Text] [Related]
16. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
17. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Mansfield PF; Rosenblum MG; Murray JL; Itoh K
Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
[TBL] [Abstract][Full Text] [Related]
19. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
20. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.
De Paola F; Ridolfi R; Riccobon A; Flamini E; Barzanti F; Granato AM; Mordenti GL; Medri L; Vitali P; Amadori D
Br J Cancer; 2003 Jan; 88(2):320-6. PubMed ID: 12610520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
